FRLN News and Press, Freeline Therapeutics Holdings plc From 10/04/23

Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events ...

Frontline plc (the “Company”) announces the filing of its half yearly report for the six months ended June 30, 2023. The half yearly report can be downloaded from the Company’s website www.frontlineplc.cy or from the link below. September 14, 2023 Frontline plc...

Please find enclosed the presentation of Frontline plc´s second quarter 2023 results to be held on the webcast / conference call 24 August, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 – 12 of the Norwegian Securities Trading ...

FRONTLINE PLC REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2023 Frontline plc (the “Company” or “Frontline”), today reported unaudited results for the six months ended June 30, 2023: Highlights Highest second quarter profit since ...

Frontline plc.’s preliminary second quarter 2023 results will be released on Thursday August 24, 2023, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section ...

2023-08-15 10:47:02 ET Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Results Conference Call August 15, 2023 8:00 AM ET Company Participants Naomi Aoki - Investor Relations Michael Parini - CEO and Executive Director Pamela Foulds - Chief Medical Officer ...

2023-08-15 07:02:50 ET More on Freeline Therapeutics Freeline, Forcefield team up to develop gene therapies for heart diseases Freeline gains as NEJM publishes long-term data for hemophilia therapy Freeline begins dosing patients in confirmatory trial to treat hemoph...

Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson’s disease Management to ...

LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Parti...

LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated virus (AAV) gene therapy candidate in Gaucher disease Type 1, on Tuesday, August 1, 2023 at 8:3...